Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Ximluci 10 mg/mL solution for injection
Medicines register · Ireland

Ximluci 10 mg/mL solution for injection

Authorisation EU/1/22/1691/002 · Stada Arzneimittel AG

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Stada Arzneimittel AG (all products →)
Active substance
Ranibizumab
Clinical trials
13 clinical trials →
Dosage form
Solution for injection
Route of administration
Intravitreal use
ATC code
S01LA04
First authorised
09/11/2022
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Ranibizumab: supply and approvals

14 authorised products on the HPRA list contain Ranibizumab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 18 Nov 2026)
Recent EMA authorisation
Susvimo, 18 Sep 2026, Roche Registration GmbH
Vislyfa, 15 Jul 2026 (biosimilar), Lupin Europe GmbH
Rexatilux, 19 Jun 2026 (biosimilar), Intas Third Party Sales 2005 S.L.
Ranluspec, 10 Feb 2026 (biosimilar), Lupin Europe GmbH

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1691. It has been authorised for 4 years (since 9 November 2022). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Ranibizumab in Ireland

13 other products on the HPRA list contain Ranibizumab, from 8 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Byooviz 10 mg/ml solution for injectionSamsung Bioepis NL B.V.Centralised EU authorisationNot stated
Epruvy 10 mg/ml solution for injection (previously Ranibizumab Midas)Midas Pharma GmbHCentralised EU authorisationNot stated
Lucentis 10 mg/ml solution for injectionNovartis Europharm LimitedCentralised EU authorisationNot stated
Ranivisio 10 mg/ml solution for injectionMidas Pharma GmbHCentralised EU authorisationNot stated
Ranluspec 10 mg/mL solution for injectionLupin Europe GmbHCentralised EU authorisationNot stated
Ranluspec 10 mg/mL solution for injection in pre-filled syringeLupin Europe GmbHCentralised EU authorisationNot stated
Rexatilux 10 mg/ml solution for injectionIntas Third Party Sales 2005 S.L.Centralised EU authorisationNot stated
Rexatilux 10 mg/ml solution for injection in pre-filled syringeIntas Third Party Sales 2005 S.L.Centralised EU authorisationNot stated
RimmyrahQilu Pharma Spain S.L.Centralised EU authorisationNot stated
Susvimo 100 mg/mL solution for injectionRoche Registration GmbHCentralised EU authorisationNot stated
Vislyfa 10 mg/mL solution for injectionLupin Europe GmbHCentralised EU authorisationNot stated
Vislyfa 10 mg/mL solution for injection in pre-filled syringeLupin Europe GmbHCentralised EU authorisationNot stated

All 14 products with Ranibizumab →

The licence holder

Stada Arzneimittel AG holds 45 products on the HPRA list, with 17 different active substances; 3 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.